NASD · Healthcare · Biotechnology · USA
ImmunityBio Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
ImmunityBio is a biotechnology company developing and commercializing immunotherapies designed to activate the immune system against cancer and infectious diseases. The company's Cancer BioShield platform includes ANKTIVA, an antibody-cytokine fusion protein, along with adenovirus-vectored vaccines, natural killer cell therapies, and immunomodulators to promote immune responses.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the ImmunityBio Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: a figure this valuation depends on is missing.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on IBRX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.